Summary by Moomoo AI
Recursion Pharmaceuticals, Inc. (Recursion) filed its definitive proxy statement with the SEC, detailing its upcoming Annual Meeting of Stockholders to be held virtually on June 3, 2024. The proxy statement includes proposals for the election of three Class III directors, Blake Borgeson, R. Martin Chavez, and Dean Y. Li, whose terms are set to expire at the meeting. The statement also addresses executive compensation, with a recommendation for stockholders to approve the compensation of Named Executive Officers. The report highlights key achievements in 2023, such as clinical program advancements, significant partnerships, and the development of the Recursion OS platform. Additionally, the proxy statement outlines the company's executive compensation philosophy, emphasizing a pay-for-performance culture and alignment with stockholder interests. The company's financial performance, including a net loss for the year, is also discussed. The proxy statement includes information on the ownership of Recursion's common stock by certain beneficial owners and management, as well as potential payments upon termination or change in control for executive officers.